Breaking News

Gilead Sciences Signs Agreement with Jounce Therapeutics

Licenses Jounce’s JTX-1811, a monoclonal antibody targeting tumor-infiltrating T regulatory cells.

By: Contract Pharma

Contract Pharma Staff

Gilead Sciences Inc. has signed an agreement with Jounce Therapeutics Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, to exclusively license its JTX-1811 program.   JTX-1811 is a monoclonal antibody designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory (TITR) cells. The target of JTX-1811 is CCR8, a chemokine receptor enriched on TITR cells. When JTX-1811 binds to CCR8, it targets TIT...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters